Santen Pharmaceutical Co share price logo

Santen Pharmaceutical Co

OTC: SNPHY

Mid Cap

$12.56

-0.03

(-0.24%)

as on

Santen Pharmaceutical Co Stock Performance

as on November 20, 2026 at 6:29 am IST

  • Day's High

    $12.56
    $12.71

    1.19%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Santen Pharmaceutical Co share price movements today

Previous Close
$12.59
Open
$12.71
Volume
78.8K
Market Cap
$4.1B
Dividend Yield
1.76%
Day's Low - High
$12.56 - $12.71

Santen Pharmaceutical Co Historical Returns

1 Month Return
+ 10.56 %
3 Month Return
+ 1.32 %
1 Year Return
+ 25.04 %
3 Year Return
+ 41.12 %
5 Year Return
0 %

Santen Pharmaceutical Co Stock Fundamentals & Key Indicators

Check Santen Pharmaceutical Co market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.1B

EPS (TTM)

122.67

Dividend Yield

1.76%

PE Ratio (TTM)

17.1

Industry PE ratio

4.56

PEG Ratio

0.58

Return On Equity TTM

13.12%

Santen Pharmaceutical Co vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Santen Pharmaceutical Co with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
NA$4.1BNA17.1056.15%1.76%
StrongBuy$1.3T418.27%44.7683.63%0.50%
StrongBuy$505.6B143.93%49.0573.72%2.42%
Buy$670.9B64.00%41.3467.56%1.94%
StrongBuy$286.8B60.70%25.6177.59%1.76%

Stock Returns calculator for Santen Pharmaceutical Co Stock including INR - Dollar returns

The Santen Pharmaceutical Co stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Santen Pharmaceutical Co investment value today

Current value as on today

₹1,31,818

Returns

₹31,818

(+31.82%)

Returns from Santen Pharmaceutical Co Stock

₹25,037 (+25.04%)

Dollar Impact

₹6,780 (+6.78%)

Indian Investors' Interest in Santen Pharmaceutical Co Stock

Search interest for Santen Pharmaceutical Co Stock has decreased by -25% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-25% versus previous 30 day period

Santen Pharmaceutical Co Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
72,389
73,417
77,027
79,132
74,771
71,633
74,199
82,346
69,865
74,332
Gross Profit
42,365
43,986
44,882
45,088
42,766
40,131
39,239
50,584
38,186
42,720
Operating Income
12,750
12,350
11,058
2,383
13,155
12,079
10,460
17,386
8,168
11,295
EBITDA
17,067
16,595
15,744
20,587
17,863
15,052
15,583
22,024
12,948
16,098
Interest Expense
168
486
703
1,683
407
330
323
521
747
343
Depreciation
4,031
4,902
4,685
4,560
4,707
4,335
4,631
4,637
4,780
4,231
Income Before Tax
12,868
11,207
9,484
-3,685
13,450
10,389
10,630
19,721
8,444
11,524
Income Tax Expense
2,456
2,344
2,179
-3,808
2,843
2,292
2,338
3,873
1,149
3,246
Net Income
10,414
8,866
7,332
29
10,633
8,139
8,017
15,830
7,288
8,253
Net Profit Margin
58.52%
59.91%
58.27%
56.98%
57.20%
56.02%
52.88%
61.43%
54.66%
57.47%

Santen Pharmaceutical Co Annual Profit & Loss

All numbers in Millions USD

Mar 2017
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
199,096
224,942
234,026
241,555
249,605
266,257
279,037
301,965
309,211
Gross Profit
124,130
138,564
143,262
146,724
151,384
156,586
166,087
178,709
170,677
Operating Income
32,479
38,691
45,098
33,535
37,798
35,886
-3,090
38,541
47,941
EBITDA
42,786
49,698
56,967
51,057
70,276
52,930
12,949
50,716
67,406
Interest Expense
1,565
434
2,881
2,393
1,488
1,209
1,499
2,664
2,114
Depreciation
9,882
10,896
10,969
16,573
16,768
17,055
17,249
18,178
19,465
Income Before Tax
31,822
39,261
43,117
32,091
12,418
35,616
-5,799
29,874
50,303
Income Tax Expense
8,768
4,000
11,174
10,377
5,773
8,427
9,184
3,171
10,476
Net Income
21,724
35,261
31,954
23,618
6,830
27,218
-14,948
26,642
39,622
Net Profit Margin
62.35%
61.60%
61.22%
60.74%
60.65%
58.81%
59.52%
59.18%
55.20%

Santen Pharmaceutical Co Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
10,412
8,862
7,306
123
10,633
8,139
8,017
15,830
7,288
8,279
Operating Cash Flow
2,544
25,188
31,708
13,209
12,139
16,169
9,249
21,590
5,327
14,452
Investing Cash Flow
-2,700
-1,084
-1,945
-416
-1,016
-3,462
-1,991
-1,136
-911
-7,755
Financing Cash Flow
-13,761
-5,902
-11,657
-2,711
-18,936
-13,293
-11,930
-375
-7,990
-893
Change in Cash
-12,393
19,218
17,302
12,552
89,744
-89,744
-5,919
18,490
-4,334
3,399

Santen Pharmaceutical Co Annual Cash Flow

All numbers in Millions USD

Mar 2017
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Income
23,054
35,261
31,943
21,714
6,645
27,189
-14,983
26,642
39,613
Operating Cash Flow
10,843
42,843
32,894
39,947
38,808
46,043
37,147
72,649
46,123
Investing Cash Flow
-28,201
-8,259
-2,935
-5,175
-53,355
-35,169
-26,777
-6,145
-13,756
Financing Cash Flow
-28,657
-17,631
-28,107
-12,729
-16,685
5,557
-37,220
-34,031
-52,324
Change in Cash
-47,516
17,001
1,513
20,634
-28,542
20,126
-25,111
36,679
-18,139

Global Institutional Holdings in Santen Pharmaceutical Co

Check out the Institutions with significant holdings in Santen Pharmaceutical Co.

Funds
Holdings
Shares Held
Trust for Professional Managers
0.01%
40231

Insights on Santen Pharmaceutical Co

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, SNPHY has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, SNPHY stock has moved up by 10.6%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 69.86B → 74.33B (in $), with an average increase of 6.0% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 7.28B → 8.25B (in $), with an average increase of 11.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Merck & Co., Inc. has given 39.8% return, outperforming this stock by 14.8%

About Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
OrganisationSanten Pharmaceutical Co
HeadquartersGrand Front Osaka Tower A, Kita, OS, 530-8552, JP
IndustryDrug Manufacturers - General
CEOTakeshi Ito

Key Management of Santen Pharmaceutical Co

Name

Title

Mr. Daisuke Nakata

Chief Digital & Information Officer

Ms. Kaori Itagaki

General Manager of Investor Relations Group

Ms. Mika Masunari

Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer

Mr. Shinichi Teramachi

Corp. Officer, Head of Sales and Head of Japan Sales & Marketing

Ms. Yoko Saiki

Corporate Officer & Chief Human Resources Officer

Mr. Takeshi Ito

President, CEO & Representative Director

Ms. Rie Nakajima

COO & Director

Mr. Kazuo Koshiji

CFO & Corporate Officer

Ms. Marianthi Psacha

Corporate Officer, Head of EMEA Business and International Pricing Market Access & Public Affairs

Mr. Kenji Morishima

Corporate Officer & Head of China Product Development Department

FAQs

What is Santen Pharmaceutical Co share price today?

Santen Pharmaceutical Co share price today is $12.56 as on at the close of the market. Santen Pharmaceutical Co share today touched a day high of $12.71 and a low of $12.56.

What is the 52 week high and 52 week low for Santen Pharmaceutical Co share?

Santen Pharmaceutical Co share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . Santen Pharmaceutical Co stock price today i.e. is closed at $12.56,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Santen Pharmaceutical Co's market capitalisation today?

Santen Pharmaceutical Co market capitalisation is $0.00T as on .

How to invest in Santen Pharmaceutical Co Stock (SNPHY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Santen Pharmaceutical Co on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Santen Pharmaceutical Co Stock (SNPHY) from India?

Indian investors can start investing in Santen Pharmaceutical Co (SNPHY) shares with as little as ₹93.29000091552734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹932.90 in Santen Pharmaceutical Co stock (as per the Rupee-Dollar exchange rate as on ). Based on Santen Pharmaceutical Co share’s latest price of $12.56 as on November 20, 2026 at 12:59 am IST, you will get 0.7962 shares of Santen Pharmaceutical Co. Learn more about fractional shares .